Sign up


Match Document Document Title
8697848 Method for reducing immunogenicity of therapeutic protein compositions  
The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical...
8697068 Method for treating synovial sarcoma  
Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for...
8697133 Slow release compositions  
The present invention relates to the provision of micron or sub-micron sized particles formed from one or more water-soluble crystals comprising a surface coating comprising one or more bioactive...
8697069 Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cells  
The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or...
8697070 1D05 PCSK9 antagonists  
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present des...
8697370 Biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof  
Methods for the diagnosis, prognosis and prediction of sepsis in a subject using the expression levels of the biomarkers Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) and TREM-like...
8697067 Methods for increasing the effectiveness of antibodies and/or FCY receptor-binding active ingredients  
The present invention relates to an ex vivo method for increasing the effectiveness of antibodies and Fcγ receptor-binding active ingredients, comprising the steps of: a) preparing a blood sample ...
8691221 Analgesic treatment with prolonged effect  
Use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA, in particular capable of blocking the biological activity of TrkA, for the preparation of a medicament for...
8691222 NLRR-1 antagonists and uses thereof  
NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided.
8691223 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof  
Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid...
8691224 Anti-Aβ globulomer 5F7 antibodies  
Anti-Aβ globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said ...
8685394 Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases  
Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. Such Compositions comprise inter alia an anti-CTLA-4 agent, e.g. ipilimumab or...
8685932 Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases  
Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided...
8685393 Methods and compositions for the treatment and diagnosis of systemic anthrax infection  
The present invention features methods and kits that utilize Ang-2 antagonists for the treatment, inhibition, and prevention of a systemic anthrax infection. The invention described herein also...
8685400 Modulating inflammasome activity and inflammation in the central nervous system  
Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury...
8685398 Chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer  
Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These...
8685395 Methods of antagonizing signal transduction in dorsal root ganglion cells  
Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such...
8679484 Method for removal of toxins from mucosal membranes  
The present invention provides novel mucoadhesive compounds useful in the prevention of diseases and disorders of or which are associated with the mucosal membrane.
8679471 Modulation of regulatory T cells by human IL-18  
The present invention relates to compositions and methods for modulating the presence and/or activity of regulatory T cells in a subject.
8679483 High-yield method for the production of human antibodies blocking the biological activity of a human cytokine  
The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from...
8679486 High-potency botulinum toxin formulations  
The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity...
8679785 Knobs and holes heteromeric polypeptides  
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins, heteromultimers and antibody-immunoadhesin chimeras....
8680241 Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof  
The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the...
8679540 Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications  
The present invention relates to novel pharmaceutical formulations based on aqueous colloidal suspensions for the prolonged release of one or more active principles, and to the applications,...
8679762 Method of detecting hepatitis B virus s antigen  
[PROBLEMS] To provide a probe useful in the detection of HBV or HBs antigen by which an escape mutant of hepatitis B virus (HBV) possibly occurring in a specimen can be detected; and a method of...
8679489 Inhibiting cell migration  
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the ...
8679488 Targeting of bone marrow neovasculature  
Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid...
8679485 Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis  
The present disclosure provides methodology and compositions for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an...
8679487 Anti-interleukin-4 receptor antibodies  
Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are...
8674078 Methods of using BTL-II proteins  
The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using...
8674079 Cancer cell migration and cancer cell invasion inhibitor  
Provided are an antibody which binds specifically PAR1 (protease activated receptor 1) or a fragment of the antibody which retains similar characteristics thereto; a composition containing the same...
8673309 Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1  
A method of detecting MSDX Complex-1, the method introducing a first antibody to a sample to create an antibody-sample mixture, wherein the first antibody is specific for one of fibrinogen,...
8673305 Methods of treatment with antibodies against the extracellular loops of C5aR  
The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular...
8673300 Therapeutic compositions and methods for the prevention of autoimmune diseases  
Antibodies specific for an MHC class II-autoantigen complex.
8673298 Stabilized compositions of proteins having a free thiol moeity  
Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
8673308 Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases  
Methods and therapeutic agents are disclosed for treating neurodegenerative disorders by depletion of CD8 positive T cells by using antibodies, FAb fragments of antibodies or similar agents that...
8673581 sCD40L and placental growth factor (PLGF) as biochemical marker combinations in cardiovascular diseases  
The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools...
8673299 Anti-RANTES antibodies  
The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5),...
8668909 Anti MIF antibodies  
The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor...
8668910 Antibodies that specifically bind to the EphA2 receptor  
The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent...
8668908 Method for alleviating chemotherapy side effects using extract of Dioscorea sp  
Extract fractions of Dioscorea sp. and methods of preparing the extract fractions are disclosed. The extract fractions enhance the proliferation and differentiation of bone marrow cells. Also...
8663641 Anti-PSGL-1 antibodies  
Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of...
8663636 Method of treating a malignant tumor by administering antibodies directed to DLL4  
The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described...
8664363 Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease  
Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable...
8664362 Humanized and chimeric anti-properdin antibodies  
An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3...
8664470 Mouse model of retinal degeneration  
The invention is directed to a method of producing a non-human mammal having one or more pathological characteristics of retinal degeneration and/or age-related macular degeneration. In particular,...
8663635 N-cadherin: target for cancer diagnosis and therapy  
The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers.
8663576 Detection of intraamniotic infection  
The present invention concerns the identification of biomarkers and groups or combinations of biomarkers that can be used for non-invasive diagnosis of intra-amniotic infection, and diagnostic...
8663634 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity  
The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3...
8663637 Methods and compositions for modulation of Olfml3 mediated angiogenesis  
The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be...